[Treatment guideline for breast cancer and SERM-treatment].
作者信息
Iwase Hirotaka, Yamamoto Yutaka, Kawasoe Teru
机构信息
Department of Breast and Endocrine Surgery Graduate School of Medical Sciences, Kumamoto University.
出版信息
Nihon Rinsho. 2007 Nov 28;65 Suppl 9:636-40.
PMID:18159717
Abstract
摘要
相似文献
1
[Treatment guideline for breast cancer and SERM-treatment].
Nihon Rinsho. 2007 Nov 28;65 Suppl 9:636-40.
2
Advances in adjuvant hormonal therapy for postmenopausal women.
J Clin Oncol. 2005 Mar 10;23(8):1751-9. doi: 10.1200/JCO.2005.11.038.
3
[Adjuvant antihormonal therapy for postmenopausal women with primary operable breast cancer].
Ugeskr Laeger. 2007 Jan 22;169(4):297-9.
4
Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
Minerva Ginecol. 2009 Dec;61(6):517-39.
5
[Additional effect of SERM: mammary gland].
Clin Calcium. 2004 Oct;14(10):47-51.
6
[Adjuvant treatment of breast cancer. Endocrine therapy].
Ugeskr Laeger. 2007 Sep 10;169(37):3072-6.
7
[Breast neoplasms: predictive factors for endocrine therapy ].
Nihon Rinsho. 2007 Jun 28;65 Suppl 6:148-53.
8
Tamoxifen, raloxifene and the prevention of breast cancer.
Minerva Endocrinol. 2002 Jun;27(2):127-39.
9
A 62-year-old woman with a new diagnosis of breast cancer.
JAMA. 2006 Mar 22;295(12):1434-42. doi: 10.1001/jama.295.12.1434.
10
The nature of tamoxifen action in the control of female breast cancer.
In Vivo. 2001 Jul-Aug;15(4):319-25.
Zotero 插件